What is the Study about?
The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes and Diabetic Kidney Disease in addition to regular therapy. Type 2 diabetes is a chronic disease in which the body is unable to properly use insulin, a hormone that regulates blood sugar levels, or does not produce enough insulin, typically leading to increased blood sugar levels and other complications. Diabetic kidney disease is a complication affecting the kidneys of patients with diabetes. More commonly, it develops in people who have had diabetes for at least 10 years. This study will look at the progression of kidney disease in participants with type 2 diabetes and diabetic kidney disease.
Eligibility to participate
- Are between the age of 18 – 70 years
- Have type 2 diabetes
- Have diabetic kidney disease
What is involved in the Study?
Participants will be randomly assigned (like the flip of a coin) to receive either finerenone or a placebo and come to the University of Minnesota for 12 visits over 3 years. At these visits medical history will be reviewed, an electrocardiogram (ECG) taken, and blood and urine collected for laboratory testing. Compensation is available.